THU0194 Cd4+ t cells, immunoglobulins and risk of infection in patients with rheumatoid arthritis over multiple cycles of rituximab

F. Martins, A. Bensalem, T. Bejan-Angoulvant, A. Lhommas, J. Mélet, S. Mammou, G. Thibault, L. Bernard, P. Goupille, D. Mulleman
2018 THURSDAY, 14 JUNE 2018   unpublished
Rituximab (RTX) may be responsible for infectious event in RA patients. Immunological markers may be associated with the occurrence of infections. Objectives: To evaluate lymphocyte counts and immunoglobulin concentrations over multiple cycles of RTX in RA patients, and to analyse the relationship between these markers and the occurrence of infections. Methods: Retrospective monocentric study on 94 RA patients treated with RTX. At baseline and during follow up, lymphocyte phenotyping (CD4+,
more » ... notyping (CD4+, CD3+, CD19 +cells), gammaglobulin, IgG, IgM and IgA concentration were assessed. Patients were dichotomized according to the absence or presence of infectious events. A student's test was used to compare the continuous variables and a Chi2 test or the Fisher test was used for the dichotomous variables. Results: A total of 119 infectious events occurred during follow-up, of which only 11 were serious, with respective incidences of 65 per 100 patient-years and 6 per 100 patient-years. Low IgM concentration at RTX initiation and low IgG concentration (<5 g/L) throughout follow-up were associated with an increased risk of infection. Both gammaglobulin and IgG concentrations decreased along with successive cycles of RTX in patients with infection, while they remained stable in patients without infection. Twelve patients had a CD4 +cell count<200/mm 3 during follow up, of which one with a CD4 +cell count 233/mm 3 at baseline, who subsequently presented an opportunistic infection. Conclusions: Gammaglobulin, IgM and IgG concentrations and CD4 +cell count are valuable before RTX initiation in RA patients. IgG or gammaglobulin concentration should also be monitored before each cycle. CD4 +lymphocytes monitoring should be considered in patients with low value at initiation.
doi:10.1136/annrheumdis-2018-eular.7030 fatcat:znczlwvpmbflraphuyuv44t7ge